Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
ReumatologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Annals of the rheumatic diseases
- Publicado em
- 21 out 2024
- Citações
- 56
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Cynthia Aranow, Cornelia F Allaart, Zahir Amoura, Ian N Bruce, Patricia C Cagnoli, Walter W Chatham, Kenneth L Clark, Richard Alan Furie, James Groark, Murray B Urowitz et al.
Descritores MeSH
- Rituximab
- Drug Therapy, Combination
- Immunosuppressive Agents
- Lupus Erythematosus, Systemic
- Antibodies, Monoclonal, Humanized
- Severity of Illness Index
- Female
- Humans
- Treatment Outcome
- Injections, Subcutaneous